Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Ticker SymbolINDV
Company nameIndivior PLC
IPO dateDec 24, 2014
CEOCiaffoni (Joseph J)
Number of employees1030
Security typeOrdinary Share
Fiscal year-endDec 24
Address234 Bath Road
CitySLOUGH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeSL1 4EE
Phone448043791090
Websitehttps://www.indivior.com/en
Ticker SymbolINDV
IPO dateDec 24, 2014
CEOCiaffoni (Joseph J)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data